These inflammation-enhanced models can mimic conditions like inflammatory bowel disease leading to CRC, allowing testing of candidates such as NSAIDs, IL-6/JAK-STAT inhibitors, or novel PAR-2 antagonists in a controlled setting. This evidence concerns the gene F2RL1 and inflammatory bowel disease.